Market Research Logo

Burkholderia Infections - Pipeline Review, H2 2016

Burkholderia Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections – Pipeline Review, H2 2016, provides an overview of the Burkholderia Infections (Infectious Disease) pipeline landscape.

Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkholderia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Burkholderia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Burkholderia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkholderia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkholderia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkholderia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkholderia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Burkholderia Infections Overview
Therapeutics Development
Pipeline Products for Burkholderia Infections - Overview
Pipeline Products for Burkholderia Infections - Comparative Analysis
Burkholderia Infections - Therapeutics under Development by Companies
Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes
Burkholderia Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Burkholderia Infections - Products under Development by Companies
Burkholderia Infections - Products under Investigation by Universities/Institutes
Burkholderia Infections - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals LLC
Arno Therapeutics Inc
Bavarian Nordic A/S
Emergent BioSolutions Inc
Eumedica SA
Grifols SA
Sarepta Therapeutics Inc
Soligenix Inc
Syntiron LLC
TGV-Laboratories
Vault Pharma Inc
Burkholderia Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-3100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARD-3150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkholderia pseudomallei vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkholderia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkholderia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EV-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-072 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melioidosis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Panaecin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGX-943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
temocillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burkholderia Infections - Dormant Projects
Burkholderia Infections - Discontinued Products
Burkholderia Infections - Product Development Milestones
Featured News & Press Releases
May 31, 2016: FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072
Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
Feb 21, 2014: Bavarian Nordic’s MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Burkholderia Infections, H2 2016
Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Burkholderia Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
Burkholderia Infections - Pipeline by Arno Therapeutics Inc, H2 2016
Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H2 2016
Burkholderia Infections - Pipeline by Emergent BioSolutions Inc, H2 2016
Burkholderia Infections - Pipeline by Eumedica SA, H2 2016
Burkholderia Infections - Pipeline by Grifols SA, H2 2016
Burkholderia Infections - Pipeline by Sarepta Therapeutics Inc, H2 2016
Burkholderia Infections - Pipeline by Soligenix Inc, H2 2016
Burkholderia Infections - Pipeline by Syntiron LLC, H2 2016
Burkholderia Infections - Pipeline by TGV-Laboratories, H2 2016
Burkholderia Infections - Pipeline by Vault Pharma Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Burkholderia Infections - Dormant Projects, H2 2016
Burkholderia Infections - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Burkholderia Infections, H2 2016
Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report